Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor D

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor D

Agios Pharma (AGIO) PT Raised to $90 at RBC Capital

May 7, 2018 7:39 AM EDT

RBC Capital raised its price target on Agios Pharma (NASDAQ: AGIO) to $90.00 (from $88.00) while maintaining an Outperform rating.

Analsyt Kennen MacKay said came away from the R&D day more positive towards the company's internal pipeline and R&D engine. AGIO detailed the broad IDH... More

Agios Pharma (AGIO) Reports In-Line Q1 EPS

May 4, 2018 7:05 AM EDT

Agios Pharma (NASDAQ: AGIO) reported Q1 EPS of ($1.63), in-line with the analyst estimate of ($1.63). Revenue for the quarter came in at $8.76 million versus the consensus estimate of $10.6 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

... More